Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 13/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 13/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 13/20 | 0.37 |
| ▸ | ACE | P12821 | 5/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637301 | 0.79 | FNTA (0.31) | — | |
| SCHEMBL5640435 | 0.75 | XIAP (0.41) | TPSAB1TPSD1TPSG1ACEXIAP | |
| SCHEMBL5638435 | 0.74 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1XIAPF10 | |
| SCHEMBL5638998 | 0.73 | ACE (0.51) | TPSAB1TPSD1TPSG1ACEF10 | |
| SCHEMBL5638710 | 0.70 | MMP1 (0.54) | ACEF10 | |
| SCHEMBL5638872 | 0.70 | TPSAB1 (0.56) | TPSAB1TPSD1TPSG1ACEF10 | |
| SCHEMBL5638879 | 0.67 | TPSAB1 (0.37) | TPSAB1TPSD1TPSG1ACEXIAP | |
| SCHEMBL5636758 | 0.67 | GAA (0.36) | ACE | |
| SCHEMBL5638087 | 0.66 | RAMP1 (0.40) | TPSAB1TPSD1TPSG1ACEF10 | |
| SCHEMBL5638399 | 0.65 | SRC (0.31) | ACEXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | TPSAB1 519/4885TPSD1 485/4885TPSG1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.